Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (541-550 of 713) with videos related to

Pageof 72
Sort By:
Oncotarget|February 13, 2016
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsKoichi Takahashi, Keyur Patel, Carlos Bueso-Ramos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III studyJorge Cortes, Joseph O Moore, Richard T Maziarz, et al.
Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.
Cancer|May 4, 2018
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemiaKiran Naqvi, Elias Jabbour, Jeffrey Skinner, et al.
American Journal of Hematology|July 19, 2020
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemiaYasmin Abaza, Hagop Kantarjian, Yasmin Alwash, et al.
Ejhaem|February 17, 2026
Fluoroquinolone Prophylaxis Reduces Intensive Care Unit Admission and <i>Clostridioides difficile</i> Rates in Acute Myeloid Leukemia Induction ChemotherapyCharles J Weeks, Sujith Abbagoni, Faizan Boghani, et al.
Cancer|June 1, 2019
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemiaKamal Chamoun, Hagop M Kantarjian, Xuemei Wang, et al.
American Journal of Hematology|May 29, 2015
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcomeTalha Badar, Aditya Shetty, Carlos Bueso-Ramos, et al.
Cancer|March 26, 2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, Hagop M Kantarjian, Jorge Cortes, et al.
Cancer|April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemiaSusan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
Pageof 72

Showing results (541-550 of 713) with videos related to

Sort By:
Pageof 72
Oncotarget|February 13, 2016
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsKoichi Takahashi, Keyur Patel, Carlos Bueso-Ramos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III studyJorge Cortes, Joseph O Moore, Richard T Maziarz, et al.
Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.
Cancer|May 4, 2018
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemiaKiran Naqvi, Elias Jabbour, Jeffrey Skinner, et al.
American Journal of Hematology|July 19, 2020
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemiaYasmin Abaza, Hagop Kantarjian, Yasmin Alwash, et al.
Ejhaem|February 17, 2026
Fluoroquinolone Prophylaxis Reduces Intensive Care Unit Admission and <i>Clostridioides difficile</i> Rates in Acute Myeloid Leukemia Induction ChemotherapyCharles J Weeks, Sujith Abbagoni, Faizan Boghani, et al.
Cancer|June 1, 2019
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemiaKamal Chamoun, Hagop M Kantarjian, Xuemei Wang, et al.
American Journal of Hematology|May 29, 2015
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcomeTalha Badar, Aditya Shetty, Carlos Bueso-Ramos, et al.
Cancer|March 26, 2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, Hagop M Kantarjian, Jorge Cortes, et al.
Cancer|April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemiaSusan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
Pageof 72